Advertisement

Avaxia Biologics Inc., a biotech company focused on the gastrointestinal tract, has won a federal contract worth $2.9 million to look into treatments for GI damage that follows radiation exposure, from such things as a nuclear accident.

The Biomedical Advanced Research and Development Authority, a unit of the U.S. Department of Health and Human Services, awarded Wayland-base Avaxia the two-year contract to specifically research and develop an oral antibody-based therapy to help mitigate radiation-caused GI tract damage. The total $2.9 million in based on Avaxia hitting certain milestones, according to a press release.

SOURCE

Advertisement
Advertisement